Literature DB >> 25592610

Mesenchymal stem cells: a friend or foe in immune-mediated diseases.

Marina Gazdic1, Vladislav Volarevic, Nebojsa Arsenijevic, Miodrag Stojkovic.   

Abstract

Mesenchymal stem cells (MSCs) are adult, self-renewable, multipotent cells that can be found in almost all postnatal tissues. Because of their capacity for self-renewal and differentiation into tissues of mesodermal origin and due to their immunomodulatory ability, MSCs are used in many preclinical and clinical studies as possible new therapeutic agents for the autoimmune or degenerative diseases treatment. In dependence of inflammatory environment to which they are exposed to, MSCs adopt immunosuppressive or pro-inflammatory phenotype. In the presence of high levels of pro-inflammatory cytokines or through activation of Toll-like receptor (TLR)-3, MSCs adopt an immune-suppressive phenotype and suppress the proliferation, activation and effector function of professional antigen presenting cells (dendritic cells, macrophages, B lymphocytes), T lymphocytes, NK cells, NKT cells, and neutrophils. During the early phase of inflammation, through TLR4 activation and in the presence of low levels of inflammatory cytokines, MSCs adopt a pro-inflammatory phenotype, promote neutrophil and T cell activation and enhance immune response. Here we review the current findings on the immunoregulatory plasticity of MSCs involved in regulation of immune response.

Entities:  

Mesh:

Year:  2015        PMID: 25592610     DOI: 10.1007/s12015-014-9583-3

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  75 in total

1.  Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation.

Authors:  Moïra François; Raphaëlle Romieu-Mourez; Mengyang Li; Jacques Galipeau
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Authors:  Venkata Lokesh Battula; Kurt William Evans; Brett George Hollier; Yuexi Shi; Frank C Marini; Ayyakkannu Ayyanan; Rui-Yu Wang; Cathrin Brisken; Rudy Guerra; Michael Andreeff; Sendurai A Mani
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

3.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells.

Authors:  Kazuya Sato; Katsutoshi Ozaki; Iekuni Oh; Akiko Meguro; Keiko Hatanaka; Tadashi Nagai; Kazuo Muroi; Keiya Ozawa
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

4.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

5.  Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications.

Authors:  Soufiane Ghannam; Carine Bouffi; Farida Djouad; Christian Jorgensen; Danièle Noël
Journal:  Stem Cell Res Ther       Date:  2010-03-15       Impact factor: 6.832

6.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Authors:  Roland Meisel; Andree Zibert; Maurice Laryea; Ulrich Göbel; Walter Däubener; Dagmar Dilloo
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

7.  Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism.

Authors:  Farida Djouad; Louis-Marie Charbonnier; Carine Bouffi; Pascale Louis-Plence; Claire Bony; Florence Apparailly; Céline Cantos; Christian Jorgensen; Danièle Noël
Journal:  Stem Cells       Date:  2007-05-17       Impact factor: 6.277

8.  Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression.

Authors:  Guangwen Ren; Juanjuan Su; Liying Zhang; Xin Zhao; Weifang Ling; Andrew L'huillie; Jimin Zhang; Yongqing Lu; Arthur I Roberts; Weizhi Ji; Huatang Zhang; Arnold B Rabson; Yufang Shi
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

9.  Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils.

Authors:  Sean R R Hall; Konstantin Tsoyi; Bonna Ith; Robert F Padera; James A Lederer; Zhihong Wang; Xiaoli Liu; Mark A Perrella
Journal:  Stem Cells       Date:  2013-02       Impact factor: 6.277

Review 10.  Mesenchymal stem cells and autoimmune diseases.

Authors:  Francesco Dazzi; Mauro Krampera
Journal:  Best Pract Res Clin Haematol       Date:  2011-02-23       Impact factor: 3.020

View more
  78 in total

Review 1.  Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review.

Authors:  Ann A Simones; Daniel J Beisang; Angela Panoskaltsis-Mortari; Kari D Roberts
Journal:  Pediatr Res       Date:  2017-10-25       Impact factor: 3.756

Review 2.  Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Authors:  Nicole Lopez; Sonia Ramamoorthy; Willam J Sandborn
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-04-26       Impact factor: 3.869

Review 3.  Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.

Authors:  Bojana Simovic Markovic; Tatjana Kanjevac; C Randall Harrell; Marina Gazdic; Crissy Fellabaum; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

Review 4.  Lung-resident mesenchymal stromal cells are tissue-specific regulators of lung homeostasis.

Authors:  Stefanie Noel Sveiven; Tara M Nordgren
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-05-13       Impact factor: 5.464

5.  Identification of IL-1β and LPS as optimal activators of monolayer and alginate-encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods.

Authors:  Andrea Gray; Timothy Maguire; Rene Schloss; Martin L Yarmush
Journal:  Biotechnol Prog       Date:  2015-05-28

Review 6.  The effects of cigarette smoking and nicotine on the therapeutic potential of mesenchymal stem cells.

Authors:  Carl Randall Harrell; Valentin Djonov; Vladislav Volarevic
Journal:  Histol Histopathol       Date:  2021-11-30       Impact factor: 2.303

7.  Allogeneic human umbilical cord-derived mesenchymal stem cells reduce lipopolysaccharide-induced inflammation and acute lung injury.

Authors:  Shiao-Ya Hong; Sen-Wen Teng; Willie Lin; Cheng-Yi Wang; Hen-I Lin
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

8.  Equine Hoof Stem Progenitor Cells (HPC) CD29 + /Nestin + /K15 + - a Novel Dermal/epidermal Stem Cell Population With a Potential Critical Role for Laminitis Treatment.

Authors:  Krzysztof Marycz; Ariadna Pielok; Katarzyna Kornicka-Garbowska
Journal:  Stem Cell Rev Rep       Date:  2021-05-26       Impact factor: 5.739

9.  Promotion of Differentiating Bone Marrow Mesenchymal Stromal Cells (BMSCs) into Cardiomyocytes via HCN2 and HCN4 Cotransfection.

Authors:  Xue Luo; Hongxiao Li; Xiaolin Sun; Qisheng Zuo; Bichun Li; Ye Zhu; Wei Wei; Xiang Gu
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

Review 10.  Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution.

Authors:  Anna Valeria Samarelli; Roberto Tonelli; Irene Heijink; Aina Martin Medina; Alessandro Marchioni; Giulia Bruzzi; Ivana Castaniere; Dario Andrisani; Filippo Gozzi; Linda Manicardi; Antonio Moretti; Stefania Cerri; Riccardo Fantini; Luca Tabbì; Chiara Nani; Ilenia Mastrolia; Daniel J Weiss; Massimo Dominici; Enrico Clini
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.